Does Blue Cross Blue Shield of Michigan Cover Tirzepatide (Mounjaro)?

What Tirzepatide Is and Why Coverage Rules Differ by Indication

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. The FDA approved it in May 2022 under the brand name Mounjaro for glycemic control in adults with type 2 diabetes, and in November 2023 under the brand name Zepbound for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity [1].

Coverage decisions by insurers, including BCBSM, hinge heavily on which indication appears on the prescription and the diagnosis code submitted by your provider.

Why the Two Brand Names Matter for Insurance

Mounjaro and Zepbound contain identical active ingredients at identical doses. Insurers, however, treat them as separate products because they carry different FDA-approved indications and different National Drug Codes (NDCs). A claim submitted with a diabetes diagnosis code (E11.xx) routes to your pharmacy formulary under one set of rules. A claim submitted with an obesity diagnosis code (E66.xx) routes under a different set, often with far tighter restrictions.

Submitting the wrong NDC or diagnosis code is the single most common reason tirzepatide claims are denied on BCBSM plans. Your prescribing clinician's office must verify which NDC to use before sending the prescription to the pharmacy.

The Clinical Evidence Driving Prescriber Demand

The SURPASS-2 trial (N=1,879) compared tirzepatide against semaglutide 1 mg in adults with type 2 diabetes inadequately controlled on metformin. Tirzepatide 15 mg reduced HbA1c by a mean of 2.46 percentage points versus 1.86 percentage points for semaglutide, a difference of 0.60 percentage points that reached statistical significance (P<0.001) [2]. Body weight fell 12.4 kg with tirzepatide 15 mg versus 6.2 kg with semaglutide.

For weight loss without diabetes, the SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced a 20.9% mean reduction in body weight at 72 weeks compared to 3.1% with placebo (P<0.001) [3]. These results are why clinicians increasingly prefer tirzepatide over older GLP-1 agents, and why insurance plans face mounting pressure to cover it.

How BCBSM Formularies Are Structured

BCBSM is not a single plan. It operates several distinct product lines: Blue Care Network (BCN, the HMO arm), PPO commercial plans, Medicare Advantage (through BCN Advantage and BCBSM Advantage), and Medicaid managed care through Blue Cross Complete of Michigan. Each product line maintains its own formulary, and formularies can vary further by employer group.

Commercial PPO and BCN HMO Plans

On most BCBSM commercial PPO and BCN HMO plans as of 2025, tirzepatide appears on the specialty tier. Specialty-tier cost-sharing typically means you pay 25 to 33% coinsurance after your deductible, which on a $1,000+ monthly medication can exceed $300 per fill even after insurance pays its share.

The plan's pharmacy benefit determines whether tirzepatide is covered at all for your specific diagnosis. Employer groups that self-fund their benefits (which describes the majority of large Michigan employers) can elect to exclude obesity medications from coverage entirely, even if BCBSM administers the plan. Self-funded plan exclusions are common for weight-loss drugs because the Employee Retirement Income Security Act (ERISA) gives employers wide latitude over benefit design [4].

Medicare Advantage Plans

Traditional Medicare Part D has historically excluded drugs "used for weight loss" under statute. That exclusion applies to Zepbound when prescribed for obesity alone. Mounjaro prescribed for type 2 diabetes, however, is a covered Part D drug because diabetes is not an excluded indication. Some BCBSM Medicare Advantage plans have begun adding Zepbound coverage for members with a documented obesity-related comorbidity, but you must check your specific Evidence of Coverage document.

The Treat and Reduce Obesity Act, if enacted, would remove Medicare's statutory exclusion for obesity pharmacotherapy, but as of early 2025 it has not passed [5].

Blue Cross Complete (Medicaid Managed Care)

Michigan Medicaid generally covers Mounjaro for type 2 diabetes with prior authorization. Coverage of Zepbound for obesity under Michigan Medicaid is more restricted. The Michigan Department of Health and Human Services publishes the Medicaid drug policy, and Blue Cross Complete follows that policy for its managed-care enrollees [6].

Prior Authorization Requirements for Tirzepatide on BCBSM Plans

Prior authorization (PA) is required on essentially all BCBSM plan types for tirzepatide. The PA process exists because specialty-tier GLP-1 and GIP/GLP-1 medications carry significant per-member costs. Understanding the criteria in advance helps your provider submit a complete, approvable request on the first attempt.

Typical PA Criteria for Mounjaro (Type 2 Diabetes Indication)

BCBSM commercial plans generally require all of the following for Mounjaro PA approval:

• A confirmed type 2 diabetes diagnosis with an HbA1c above a plan-specified threshold (commonly 7.5% or higher at baseline)
• Documentation that the patient has tried and had an inadequate response to metformin at a therapeutic dose, unless metformin is contraindicated or not tolerated
• Confirmation that the prescriber is an internist, family medicine physician, endocrinologist, or other provider with prescriptive authority appropriate for diabetes management
• Current HbA1c lab value dated within the prior 90 days included with the PA request

The American Diabetes Association's 2024 Standards of Care recommend GLP-1 receptor agonists and dual GIP/GLP-1 agonists as preferred second-line agents in type 2 diabetes when cardiovascular disease, heart failure, or chronic kidney disease is present, or when additional weight loss is a treatment goal [7]. Citing this guideline language in the PA letter strengthens the clinical justification.

Typical PA Criteria for Zepbound (Obesity Indication)

Weight-management PA criteria on BCBSM plans that do cover Zepbound commonly include:

• BMI of 30 or higher, or BMI of 27 or higher plus at least one documented comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or type 2 diabetes)
• Documentation of a structured lifestyle intervention lasting at least three to six months with an inadequate weight-loss response (typically defined as less than 5% body weight lost)
• Prior trial of another anti-obesity medication, such as orlistat, phentermine-topiramate, or naltrexone-bupropion, depending on the plan's step-therapy protocol

The Obesity Society and the American Association of Clinical Endocrinology (AACE) 2023 guidelines classify tirzepatide as a high-efficacy anti-obesity medication and recommend it as an appropriate first-line pharmacologic option in patients with obesity-related complications [8].

Step Therapy: What You May Need to Try First

Step therapy requires patients to try and fail less expensive medications before the plan approves the preferred drug. BCBSM applies step therapy to GLP-1 and GIP/GLP-1 agents on most plan types.

Diabetes Step Therapy

For the diabetes indication, most BCBSM commercial formularies require:

1. Metformin at a therapeutic dose (typically 1,000 to 2,000 mg daily) for at least 90 days, unless contraindicated by eGFR <30 mL/min/1.73m² or intolerance
2. One additional oral agent or a lower-tier injectable, such as a sulfonylurea (glipizide, glimepiride) or an SGLT-2 inhibitor (empagliflozin, dapagliflozin)

Documented intolerance (GI adverse effects severe enough to require discontinuation, or lactic acidosis risk) can waive the metformin step. Your provider should submit the specific adverse effect, date of onset, and discontinuation date.

Obesity Step Therapy

Step therapy for Zepbound may require prior trial of a lower-tier anti-obesity medication. Semaglutide 2.4 mg (Wegovy), if on the plan formulary at a lower tier, might itself be required before Zepbound is approved. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [9]. If a patient tried Wegovy and achieved less than 5% weight loss, that documented failure supports a Zepbound PA.

The HealthRX Step-Therapy Documentation Framework for Tirzepatide PA:

| Step | What to Document | Minimum Duration | |------|-----------------|-----------------| | 1 | Diagnosis (ICD-10 code, lab values) | Current (within 90 days) | | 2 | Prior drug trial(s) with doses | 90 days per agent | | 3 | Inadequate response or intolerance | Dated clinical note | | 4 | Guideline citation supporting tirzepatide | ADA 2024 or AACE 2023 | | 5 | Comorbidity burden (CVD, CKD, OSA, etc.) | Problem list or SOAP note |

Providing all five elements in the initial PA letter reduces the rate of first-pass denials significantly on commercially insured patients.

What Happens After a Denial: Appeals and Exceptions

A denial is not a final answer. BCBSM must follow Michigan insurance law and federal regulations governing internal and external appeals.

Internal Appeal

File an internal appeal within 180 days of receiving the denial notice (the specific deadline will appear on the Explanation of Benefits or denial letter). Your provider should submit a letter of medical necessity that addresses each specific denial reason. Common denial reasons include "not medically necessary," "step therapy not satisfied," or "not a covered benefit."

The appeal letter should quote directly from relevant guidelines. The American Heart Association's 2023 scientific statement on obesity and cardiovascular disease notes that "pharmacologic treatment of obesity reduces cardiovascular risk in patients with established disease" and recommends treating obesity as a cardiovascular risk factor [10]. This framing can shift a denial based on "cosmetic" or "weight loss only" reasoning.

External Appeal and Independent Medical Review

If the internal appeal fails, Michigan residents have the right to an independent external review under the Michigan Insurance Code. An Independent Review Organization (IRO) assigned by the Michigan Department of Insurance and Financial Services (DIFS) reviews the clinical evidence. IRO decisions are binding on the insurer.

Exception Requests

If tirzepatide is not on your plan formulary at all, a formulary exception request asks the plan to cover a non-formulary drug at the formulary rate. The standard requires showing that all formulary alternatives are contraindicated, have been tried and failed, or are clinically inferior for your specific situation.

Cost Without Insurance and Savings Programs

The list price for a 4-week supply of Mounjaro or Zepbound ranges from approximately $1,023 to $1,069 depending on dose and pharmacy. For patients who cannot get insurance coverage, several cost-reduction pathways exist.

Eli Lilly's Savings Card

Eli Lilly offers a savings card for Mounjaro that reduces the monthly cost to $25 per fill for eligible commercially insured patients, and a separate Zepbound savings card with a similar structure. These cards are not usable with Medicare, Medicaid, or any government-funded plan. Eligibility and terms change periodically; patients should verify current terms at Lilly's official program pages.

Compounded Tirzepatide

During the FDA drug shortage period, compounding pharmacies produced tirzepatide at lower cost. The FDA removed tirzepatide from its shortage list in October 2024, which means compounding pharmacies may no longer legally produce copies of FDA-approved tirzepatide formulations under the Section 503A/503B shortage exemption [11]. Patients should ask their provider about the current legal status of compounded tirzepatide before pursuing this route.

Patient Assistance Programs

Eli Lilly's Lilly Cares Foundation offers a patient assistance program for patients who meet income requirements (generally household income at or below 400% of the federal poverty level) and lack adequate prescription coverage. The program may provide Mounjaro or Zepbound at no cost for qualifying patients.

How to Work With Your Provider to Maximize Approval Odds

A complete, well-documented PA request submitted on the first attempt is the most reliable way to get tirzepatide covered quickly.

Before the Appointment

Gather your last two HbA1c results (for diabetes indication) or a recent weight measurement with BMI calculation (for obesity indication). Bring a list of every diabetes or weight-loss medication you have tried in the past three years, including doses, duration, and reason for discontinuation.

At the Appointment

Ask your provider to document the clinical rationale in the visit note using language that mirrors PA criteria. A note that reads "Patient has type 2 diabetes with HbA1c of 8.4% despite metformin 2,000 mg daily and empagliflozin 10 mg daily for 6 months" is far more approvable than a note that simply states "diabetes, poorly controlled."

After Submission

PA decisions on specialty medications are required within 72 hours for urgent requests and within 14 calendar days for standard requests under Michigan insurance regulations. If you have not heard within that window, call BCBSM's pharmacy PA line directly and ask for a status update.

Key Differences Between BCBSM Plan Types at a Glance

| Plan Type | Mounjaro (Diabetes) | Zepbound (Obesity) | Notes | |-----------|--------------------|--------------------|-------| | Commercial PPO (fully insured) | Covered with PA | Covered with PA on most plans | Self-funded groups may exclude | | BCN HMO | Covered with PA | Covered with PA on most plans | Step therapy applies | | Medicare Advantage | Covered (Part D, diabetes) | Variable; check EOC | Statutory exclusion for weight loss may apply | | Blue Cross Complete (Medicaid) | Covered with PA | Restricted | Michigan Medicaid drug policy governs | | Self-funded employer plan | Employer's discretion | Employer's discretion | ERISA preempts state benefit mandates |